All In Biotech

Free tool

FAERS Monitor: Cardizem La

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021392 or its brand name (Cardizem La, Diltiazem Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

12,237

Serious

10,144

83% of reports

Hospitalization

5,561

Death reported

2,820

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea1,394
  • pain1,244
  • fatigue1,212
  • fall1,078
  • diarrhoea949
  • arthralgia940
  • headache938
  • dizziness930
  • nausea914
  • pruritus887
  • drug ineffective886
  • hypotension856
  • pyrexia852
  • off label use826
  • hypersensitivity756

Reports by year received

View as table
YearReports
2004398
2005412
2006264
2007193
2008207
2009201
2010243
2011224
2012344
2013306
2014248
2015299
2016358
2017353
2018358
2019390
2020541
2021895
20221,440
20231,117
20241,353
20251,308
2026785

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypotensionSignal8567.46.94,725
hypersensitivitySignal7567.06.63,919
fallSignal1,0785.65.34,102
dyspnoeaSignal1,3944.24.03,535
pyrexiaSignal8524.24.02,136
pruritusSignal8874.03.72,003
arthralgiaSignal9403.93.72,053
painSignal1,2443.53.32,264
dizzinessSignal9303.23.01,444
fatigueSignal1,2122.72.51,320
headacheSignal9382.62.4927
diarrhoeaSignal9492.52.4902
nausea9142.01.9463
off label use8261.61.5205
drug ineffective8861.21.120

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.